文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

减低强度单倍体骨髓移植治疗儿童重型镰状细胞病:BMT CTN 1507

Reduced-Intensity Haploidentical Bone Marrow Transplantation in Children with Severe Sickle Cell Disease: BMT CTN 1507.
PubMed 文献 · Blood Adv · 2026-10-28

多中心单臂II期试验纳入41例5-14.99岁重型镰状细胞病患儿,39例接受减低强度单倍体骨髓移植。2年无事件生存率79.3%,总生存率94.5%,FEV1%预测值改善且eGFR下降提示高滤过缓解。移植失败和GVHD对无事件生存有负面影响,但该方案对无匹配同胞供者患儿有前景。

要点

  • 2年无事件生存率79.3%,总生存率94.5%。
  • FEV1%预测值从79.5升至95.7(p=0.014),eGFR从174降至127 mL/min/1.73m2(p<0.001)。
  • 连续脑MRI未发现新发或进展性脑梗死(n=22)。

核心结论

  • 减低强度单倍体骨髓移植联合移植后环磷酰胺对缺乏匹配同胞供者的重型镰状细胞病患儿是有前景的治疗选择。

研究设计与样本

  • 多中心、单臂、II期试验(NCT03263559),纳入41例5.00-14.99岁重型镰状细胞病患儿,39例(95%)接受移植。

主要发现

  • 2年无事件生存率为79.3%(95%CI: 62.8%, 89.1%),总生存率为94.5%(95%CI: 79.7%, 98.6%)。
  • FEV1%预测值从79.5增至95.7(p=0.014),eGFR从174降至127 mL/min/1.73m2(p<0.001)。
  • 连续脑MRI中心裁定未发现新发或进展性脑梗死(n=22)。
  • 移植失败和GVHD对无事件生存有负面影响。

关键数值与推荐

  • 移植方案包括羟基脲30mg/kg/天(第-60天至第-10天),随后给予胸腺球蛋白、塞替派、氟达拉滨、环磷酰胺和全身照射(200 cGy)。
  • GVHD预防包括移植后环磷酰胺、西罗莫司和吗替麦考酚酯。

临床怎么用

  • 对于无匹配同胞供者的重型镰状细胞病患儿,可考虑减低强度单倍体骨髓移植联合移植后环磷酰胺。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This is a multi-center, single-arm, phase-II, trial (NCT03263559) of haploidentical bone marrow transplant (BMT) for children with severe sickle cell disease (SCD). Eligible participants were children 5.00 - 14.99 years of age with stroke (silent or overt), abnormal transcranial Doppler cerebral arterial velocity > 200 cm/sec with intracranial vasculopathy, severe acute chest syndrome (ACS) or recurrent vaso-occlusive pain. The primary outcome was 2-year event-free survival (EFS; alive and disease-free). The transplant regimen included hydroxyurea 30mg/kg/day (Day-60 to Day-10), followed by thymoglobulin, thiotepa, fludarabine, cyclophosphamide, and total body irradiation (200 cGy). Graft-versus-host disease (GVHD) prophylaxis included post-transplant cyclophosphamide (PTCy), sirolimus and mycophenolate mofetil. Forty-one participants were enrolled from 18 sites and 95% (39/41) proceeded to BMT. The median age at enrollment was 12.5 years; 98% (38/39) had hemoglobin SS disease, and 82.1% (32/39) had donors mismatched at 4 HLA-loci. The most common indication for BMT was a qualifying neurological event in 69% (27/39), including 15 with overt stroke. Nine participants had recurrent vaso-occlusive pain and 5, severe ACS. The 2-year EFS and overall survival were 79.3% (95% CI: 62.8%, 89.1) and 94.5% (95% CI: 79.7%, 98.6%), respectively. FEV1% predicted increased from 79.5 to 95.7 at 2 years (p=0.014), and eGFR declined from 174 to 127 mL/min/1.73m2 (p<0.001), indicating resolved hyperfiltration. No new or progressive cerebral infacts were detected by serial brain MRI per central adjudication (n=22). While graft failure and GVHD negatively impacted EFS, reduced-intensity haploidentical BMT with PTCy is a promising therapy for children who lack a matched sibling donor.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Walters MC, Kassim AA, Eapen M, et al. Reduced-Intensity Haploidentical Bone Marrow Transplantation in Children with Severe Sickle Cell Disease: BMT CTN 1507. Blood Adv. 2026. PMID: 42950248. doi:10.1182/bloodadvances.2026021576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。